Skip to Main Content

Alnylam Pharmaceuticals Inc. scored its third approval from the US Food and Drug Administration in as many years Monday, this time for a medicine to treat a rare disease that affects the kidneys.

The rare disorder — called primary hyperoxaluria type 1 — causes a buildup of oxalate in the body, which when not filtered properly can cause kidney and bladder stones.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!